TP-0463518

N/A

Report date: 2022/11/17 20:00:51
NME

Base Information

Drug NameTP-0463518
Drug Alias NameTP-0463518TS-143BGE-117
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHypoxia-inducible factor 1 alpha inhibitorsEndothelial PAS domain-containing protein 1 inhibitors
TargetsHypoxia-inducible factor 1 alphaEndothelial PAS domain-containing protein 1
Therapy Area/IndicationsShock, HemorrhagicAnemiaRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaJapan
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTaisho Pharmaceutical Holdings Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBioAge Labs IncTaisho Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsShock, HemorrhagicAnemiaRenal Insufficiency, Chronic

Other Information

ATC CodeN/A
Related LinksN/A